Skip to main content
Drug bottle and Pill

Compare Januvia vs. Afrezza

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Januvia (sitagliptin) and Afrezza (insulin human) are both medications used to manage diabetes, but they belong to different medication classes and have distinct uses. Januvia is a dipeptidyl peptidase-4 (DPP-4) inhibitor taken orally once daily, while Afrezza is an ultra rapid-acting insulin that is inhaled at the start of meals. Januvia is specifically approved for Type 2 diabetes, whereas Afrezza is approved for both Type 1 and Type 2 diabetes. Januvia does not typically cause weight changes, but Afrezza can lead to weight gain. Common side effects of Januvia include a runny nose and sore throat, while Afrezza may cause low blood sugar and cough. Afrezza is not suitable for people with lung conditions like asthma or chronic obstructive pulmonary disease (COPD), whereas Januvia requires caution in those with kidney issues. Additionally, both medications can be combined with other diabetes medications for better blood sugar control, but this requires blood sugar monitoring due to the increased risk of low blood sugar.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.